Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer

Journal of Surgical Oncology

Volumn 107, Issue 7, 2013, Pages 767-771

  Lin, Qunying ^a   Chen, Tingjian ^a   Lin, Qingyu ^a   Lin, Guosheng ^a   Lin, Juan ^a   Chen, Guohuan ^a   Guo, Lijing ^a  

^a PUTIAN UNIVERSITY   (China)

Author keywords

lung cancer; microRNA; miR 19a; prognosis; serum

Indexed keywords

MICRORNA; MICRORNA 19A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84878300205     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23312     Document Type: Article

References (34)

1. Papadimitrakopoulou V:, Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1315-1326.
2. Siegel R, Desantis C, Virgo K, et al.: Cancer treatment and survivorship statistics 2012. CA Cancer J Clin 2012; 62: 220-241.
3. Selbach M, Schwanhausser B, Thierfelder N, et al.: Widespread changes in protein synthesis induced by microRNAs. Nature 2008; 455: 58-63.
4. Broderick JA, Zamore PD:, MicroRNA therapeutics. Gene Ther 2011; 18: 1104-1110.
5. Lujambio A, Lowe SW:, The microcosmos of cancer. Nature 2012; 482: 347-355.
6. Hossain A, Kuo MT, Saunders GF:, Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 2006; 26: 8191-8201.
7. Li H, Bian C, Liao L, et al.: miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat 2011; 126: 565-575.
8. Yu J, Ohuchida K, Mizumoto K, et al.: MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol Ther 2010; 10: 748-757.
9. Chen L, Jiang M, Yuan W, et al.: miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 2012; 25: 156-161.
10. Wang M, Gu H, Wang S, et al.: Circulating miR-17-5p and miR-20a: Molecular markers for gastric cancer. Mol Med Report 2012; 5: 1514-1520.
11. Tan X, Qin W, Zhang L, et al.: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011; 17: 6802-6811.
12. Zuo Z, Calin GA, de Paula HM, et al.: Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011; 118: 413-415.
13. Mitchell PS, Parkin RK, Kroh EM, et al.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
14. Navarro A, Marrades RM, Vinolas N, et al.: MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 2009; 76: 162-169.
15. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, et al.: MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009; 101: 707-714.
16. Iyevleva AG, Kuligina E, Mitiushkina NV, et al.: High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. Breast Cancer Res Treat 2012; 131: 1049-1059.
17. Liu M, Wang Z, Yang S, et al.: TNF-alpha is a novel target of miR-19a. Int J Oncol 2011; 38: 1013-1022.
18. Harada M, Pokrovskaja-Tamm K, Soderhall S, et al.: Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 2041-2050.
19. Nagel S, Venturini L, Przybylski GK, et al.: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma 2009; 50: 101-108.
20. Zhang J, Xiao Z, Lai D, et al.: miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer. Br J Cancer 2012; 107: 352-359.
21. Wang YX, Zhang XY, Zhang BF, et al.: Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 2010; 11: 50-54.
22. Xu XM, Wang XB, Chen MM, et al.: MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett 2012; 322: 148-158.
23. Zhang X, Yu H, Lou JR, et al.: MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 2011; 286: 1429-1435.
24. Qin X, Wang X, Wang Y, et al.: MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A 2010; 107: 3240-3244.
25. Mu P, Han YC, Betel D, et al.: Genetic dissection of the miR-17∼92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 2009; 23: 2806-2811.
26. Olive V, Bennett MJ, Walker JC, et al.: miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23: 2839-2849.
27. Humphreys KJ, Cobiac L, Le Leu RK, et al.: Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 2012; [Epub ahead of print].
28. Chen X, Ba Y, Ma L, et al.: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
29. Liu R, Chen X, Du Y, et al.: Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58: 610-618.
30. Cao Y, Yu SL, Wang Y, et al.: MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumour Biol 2011; 32: 179-188.
31. Ventura A, Young AG, Winslow MM, et al.: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132: 875-886.
32. Pichiorri F, Suh SS, Ladetto M, et al.: MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008; 105: 12885-12890.
33. Takakura S, Mitsutake N, Nakashima M, et al.: Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 2008; 99: 1147-1154.
34. Liang Z, Li Y, Huang K, et al.: Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 2011; 28: 3091-3100.